Related Experiment Videos
Intraprostatic concentration of ciprofloxacin and its activity against urinary pathogens
Abstract:
The in-vitro activity of ciprofloxacin against 376 urinary pathogens was determined. The minimal inhibitory concentrations for 90% of the Enterobacteriaceae were 0.03-0.23 mg/l, for Pseudomonas aeruginosa 0.37 mg/l, for Streptococcus faecalis 0.75 mg/l and for Staphylococcus aureus 0.92 mg/l. A 100 mg dose of ciprofloxacin was administered intravenously to 25 patients undergoing prostatectomy. The concentrations in prostate and serum were measured at different intervals. Peak levels in prostate were 3.0 micrograms/g attained 20 min after administration. Peak serum levels were 1.2 mg/l attained 20 min after administration. Serum and prostate elimination was slowly. The overall serum: prostate ratio 1:2.1.
Insights
Ciprofloxacin demonstrates potent in-vitro activity against common urinary pathogens. Intravenous administration achieved favorable concentrations in prostate tissue, suggesting efficacy for prostate infections.
Area of Science:
- Pharmacology
- Microbiology
- Urology
Background:
- Urinary tract infections (UTIs) are common, often caused by resistant bacteria.
- Ciprofloxacin is a fluoroquinolone antibiotic with broad-spectrum activity.
- Understanding drug penetration into prostate tissue is crucial for treating prostatitis.
Purpose of the Study:
- To evaluate the in-vitro activity of ciprofloxacin against clinical urinary isolates.
- To determine the pharmacokinetic profile of ciprofloxacin in human prostate tissue and serum following intravenous administration.
Main Methods:
- In-vitro susceptibility testing of ciprofloxacin against 376 urinary pathogens.
- Intravenous administration of 100 mg ciprofloxacin to 25 patients undergoing prostatectomy.
- Measurement of ciprofloxacin concentrations in serum and prostate tissue at various time points.
Main Results:
- Ciprofloxacin exhibited low minimal inhibitory concentrations (MICs) against Enterobacteriaceae (0.03-0.23 mg/l) and other key pathogens.
- Peak prostate concentrations of 3.0 µg/g were reached 20 minutes post-administration.
- Peak serum concentrations were 1.2 mg/l at 20 minutes, with a serum to prostate ratio of 1:2.1.
Conclusions:
- Ciprofloxacin shows significant in-vitro efficacy against a wide range of urinary pathogens.
- Achieved prostate tissue concentrations exceed MICs for many common uropathogens, indicating potential therapeutic value for prostate infections.